PBAC waa hay'ad khabiir ah oo madax-banaan oo ay magacawday dawladda Australia. Xubnaha waxaa ka mid ah dhakhaatiir, xirfadlayaal caafimaad, dhaqaaleyahanno caafimaad iyo wakiilo macaamiisha ah.
Doorkoodu waa inay ku taliyaan dawooyin cusub oo lagu taxay qorshaha faa'iidooyinka dawooyinka (PBS). Daawo cusub lama qori karo ilaa guddigu soo jeediyo talo togan. PBAC waxay kulmaan saddex jeer sannadkii, badanaa March, July iyo November.
Boggan:
Ajandaha kulanka PBAC ee soo socda:
November 2020
Lymphoma iyo CLL soo gudbinta ajandayaasha soo socda
Noofambar 2020 lymphoma/CLL soo gudbinta ajandaha
| Nooca soo gudbinta | Magaca daawada iyo kafaala qaadka | Nooca daroogada iyo isticmaalka | Liiska uu codsaday kafaala-qaadayaasha & ujeeddada |
| Liiska cusub (soo gudbin yar) | Ibrutinib | Leukemia lymphocytic chronic (CLL); Lymphocytic lymphoma (SLL); lymphoma unugga mantle | Si aad u codsato maamulka Liisaska loo baahan yahay ee kiniiniga ibrutinib ee ku jira xaalad la mid ah kaabsoosha hore u taxan. |
| Liiska cusub (soo gudbin yar) | Mogamulizumab (Kyowa Kirin) | lymphoma T-cell ee maqaarka (CTCL) | Dib u soo gudbinta si aad u codsato Qaybta 100 (maalgelinta hufan ee daaweynta kemotherabi) Maamulka Looga baahan yahay liiska bukaannada soo noqnoqday ama CTCL ee hore loogu daweeyay ugu yaraan hal daawayn nidaam oo hore |
Natiijooyinka kulanka PBAC
July 2020
Lymphoma iyo CLL soo gudbinta & natiijooyinka
Luulyo 2020 natiijooyinka kulanka PBAC ee lymphoma iyo gudbinta CLL
| Daawooyinka, kafaala-qaadka, nooca soo gudbinta | Nooca ama isticmaalka daroogada | Liisaska uu codsaday kafaala qaadaha/ujeedada soo gudbinta | Natiijada PMAC |
Venetoclax (AbbVie) U beddel liiska (soo gudbinta yar) | Cudurka leukemia ee joogtada ah (CLL) | Dib-u-soo-celinta si loo codsado liisaska loo baahan yahay ee Hay'adda, oo ay weheliso Obinutuzumab, ee daaweynta safka koowaad ee bukaannada qaba CLL kuwaas oo leh xaalado wada-jir ah oo ku salaysan fludarabine kiimoterabi | PBAC waxay ku talisay liiska venetoclax oo ay weheliso obinutuzumab daawaynta safka kowaad ee bukaanada qaba CLL kuwaas oo qaba xaalado wada nool oo aan ku haboonayn kiimiko-immunotherapy ku salaysan fludarabine. |
| Acalabrutinib (AstraZeneca) | Lymphocytic leukemia (CLL) ama lymfocytic lymphoma yar (SLL) | Si aad u codsato liiska Maamulka Looga Baahan yahay ee daawaynta bukaanka (ama monotherapy ahaan ama ay weheliso obinutuzumab) leh CLL ama SLL oo aan hore loo daawayn oo loo arko inaanay ku habboonayn daaweynta analoogga purine. Codsi labaad ayaa ahaa in la isticmaalo kaliya kooxda-hoosaadka bukaanada leh tirtirka 17p. | PBAC ma aysan yeelin ku tali liiska acalabrutinib, si loogu isticmaalo monotherapy ahaan ama lagu daro obinutuzumab, daaweynta safka koowaad ee bukaanada qaba CLL ama SLL kuwaas oo loo arko inaysan ku haboonayn daaweynta analoogga purine. PBAC waxay tixgelisay in korodhka waxtarka wax-ku-oolnimada kharashka uu ahaa mid aan la aqbali karin oo sarreeya oo aan la hubin qiimaha la soo jeediyay. |
Mogamulizumab (Kyowa Kirin) | lymphoma T-cell ee maqaarka (CTCL) | Si aad u codsato Qaybta 100 (Maalgelinta Waxtarka Chemotherapy) ee Hay'adda Looga Baahan Yahay (Qoran) liiska bukaannada soo noqnoqday ama CTCL ee hore loogu daweeyay ugu yaraan hal daawayn nidaam oo hore ah. | PBAC kuma talin liiska mogamulizumab ee daawaynta bukaanada soo noqnoqday ama CTCL dib u dhac ku yimid ka dib ugu yaraan hal daawaynta nidaamka hore ee xaaladan. PBAC waxay tixgelisay in xadka faa'iidada mogamulizumab marka la eego horumarka badbaadada xorta ah iyo guud ahaan badbaadada aan la hubin. Intaa waxaa dheer, PBAC waxay tixgelisay in korodhka wax-ku-oolnimada kharash-ku-oolnimada uu ahaa mid aan la aqbali karin oo sarreeya oo aan la hubin qiimaha la soo jeediyay, iyo saameynta maaliyadeed ee la qiyaasay waxay ahayd mid aan la hubin. |
Maarso 2020 Ajendaha kulanka PBAC ee lymphoma/CLL & sugitaanka sugitaanka ee laga bilaabo Noofambar 2019
| Magaca daawada iyo kafaala qaadka | Nooca hoose | Liiska la codsaday iyo ujeedada | Natiijada PBAC |
| Ibrutinib (Janssen) | Lymphocytic leukemia (CLL) ama lymfocytic lymphoma yar (SLL) | Dib-u-soo-celinta si aad u codsato lacag-celinta PBS ee daaweynta CLL ama SLL oo leh caddayn hal ama in ka badan 17p koromosoomyada tirtirka | PBAC waxay ku talisay liiska PBS ee ibrutinib ee daawaynta safka kowaad ee CLL/SLL oo la tirtiray 17p -wali waxaa la sugayaa in la qoro, laga soo bilaabo Noofambar 2019 |
| Acalabrutinib (AstraZeneca) | Lymphocytic leukemia (CLL) ama lymfocytic lymphoma yar (SLL) | Si aad u codsato liiska PBS ee daawaynta bukaanka dib u soo noqday ama CLL ama SLL aan ku habboonayn daaweynta analoogga purine | PBAC waxay ku talisay liiska acalabrutinib ee daawaynta bukaanada qaba R/R CLL/SLL ee daawaynta safka labaad - sugitaanka in lagu noqdo PBS liiska ilaa Maarso 2020 |
| Pembrolizumab (MSD) | Dhexdhexaadiyaha aasaasiga ah ee B-cell lymphoma (PMBCL) | Dib u soo gudbinta si aad u codsato liiska PBS ee daawaynta soo noqnoqotay ama dib u dhac ku yimid PMBCL | PBAC waxay ku talisay liiska PBS ee pembrolizumab ee R/R PMCL - wdoonaya inuu noqdo PBS liiska ilaa Maarso 2020 |
